GUIDANCE DOCUMENT
Guidance for Industry: Transition from Temporary Policy During the COVID-19 Public Health Emergency Regarding the Qualified Exemption from the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption April 2023
- Docket Number:
- FDA-2023-D-1031
- Issued by:
-
Guidance Issuing OfficeHuman Foods Program
This guidance is intended for farms subject to the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (Produce Safety Rule) (21 CFR Part 112). For certain farms, the Produce Safety Rule provides a qualified exemption; qualified exempt farms are subject to modified rule requirements. During the COVID-19 public health emergency as declared by the Secretary of the U.S. Department of Health and Human Services (HHS), FDA provided certain temporary flexibilities related to eligibility criteria for the qualified exemption. This document communicates FDA’s current thinking on how, when the COVID-19 public health emergency expires, qualified exempt farms may transition away from those temporary policies and back to the qualified exemption eligibility criteria as established in the Produce Safety Rule.
FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe our current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.
Related Information
- Constituent Update: FDA Issues Guidance for Qualified Exempt Farms that Utilized Temporary Flexibilities During COVID-19 Public Health Emergency (April 13, 2023)
- Produce & Plant Products Guidance Documents & Regulatory Information
- Food Safety Modernization Act (FSMA)
- FSMA Final Rule on Produce Safety
- Food Safety and COVID-19 (ARCHIVED)
- FDA COVID-19 Information
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2023-D-1031.